Is Ensysce Biosciences, Inc. (ENSC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 15.2% / 30% | 176.2% / 30% | 6.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 15.2% / 33% | 176.2% / 33% | 6.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 5.4% / 33% | 62.6% / 33% | 2.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 15.2% / 33% | 176.2% / 33% | 6.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 5.4% / 33% | 62.6% / 33% | 2.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -135.4% | |
| Operating Margin | -758.7% | |
| Net Margin | -244.5% | |
| Return on Equity (ROE) | -294.4% | |
| Return on Assets (ROA) | -109.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $301,660 |
| Debt-to-Equity | 44.3 |
| Current Ratio | 1.3 |
| Total Assets | $6M |
Price & Trading
| Last Close | $0.55 |
| 50-Day MA | $0.57 |
| 200-Day MA | $1.61 |
| Avg Volume | 6.3M |
| Beta | 1.2 |
|
52-Week Range
$0.31
| |
About Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ensysce Biosciences, Inc. (ENSC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ensysce Biosciences, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ensysce Biosciences, Inc.'s debt ratio?
Ensysce Biosciences, Inc.'s debt ratio is 15.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.4%.
What are Ensysce Biosciences, Inc.'s key financial metrics?
Ensysce Biosciences, Inc. has a market capitalization of $2M. The company maintains a gross margin of -135.4% and a net margin of -244.5%. Return on equity stands at -294.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.